The goal is to Develop treatments for Zika infection during pregnancy using a marmoset model.

HIV is a major worldwide challenge that remains to be solved, and there is a continuous need to identify improved preventative and therapeutic interventions. This annual symposium provides an environment that promotes the exchange of ideas and perspectives, and fosters new collaborations, especially between junior and senior members of the research community.

The major goal is to assess the ability of Mtb-specific CD4 T cells from ART versus ART + IPT animals to active antimicrobial functions of Mtb-infected macrophages. Role: PI

Proposal:19-051 The major goal of this proposal is to vaccinate neonatal macaques with recombinant, TLR-2 stimulating, BCG vaccine, which can induce central memory T cells, and thereby generate long-term immunity against tuberculosis. We will, therefore: 1) Evaluate TH1 immune responses induced by wild type and recombinant BCG vaccine in neonatal macaques; 2) evaluate efficacy of wild type and recombinant BCG vaccines against tuberculosis in neonatal macaques; and, 3) evaluate long-term efficacy of wild type and recombinant BCG vaccines using in neonatal macaques. Role:Co-PI

The major goal of this project is to perform screening EBOV ELISA assay for 30 cynomolgus samples from Covance for UTMB.

Artemisinin is the endoperoxide-containing plant natural product used to treat malaria, a deadly disease that has killed 445,000 people in 2016 - 90% of these deaths were in Africa. The current industrial production of artemisinin employs a semi-synthetic approach, which involves the microbial fermentation of yeast containing the plant genes to produce the biosynthetic precursor, artemisinic acid, followed by four chemical transformations to yield artemisinin.

The major goal is to develop a delta-sigH -based human TB vaccine candidate that could eventually advance to clinical development. Role: PI

19-003 We propose a study to investigate the risk of TB reactivation in BCG vaccinated marmosets that are treated with Secukinumab. Role: PI

The major objective is to perform ELISPOT and ICS analysis for the UVF vaccine associated with project ImmunogenicityofSLA-LSQ adjuvant formulations in non-human primates.

19-036 This proposal is designed to determine the immunological changes induced by SIV Infection that contributes to the increased severity of mtb in infants, and the effects of early antiretroviral therapy (ART) and Immunotherapy (IDO-inhibitor treatment) on both infections by comparing viral/bacterial burdens, innate, adaptive, and pathogen specific cellular and humoral immune responses, pulmonary pathology, latency, reservoirs, and Disease Progression. Role: Sub-PI